In metastatic dMMR–MSI-H CRC, immune checkpoint inhibitors (ICIs), specifically monoclonal antibodies targeting programmed cell death 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), increase survival, but pMMR–MSI-L CRC is mainly insensitive to existing ICIs [66]. This evidence concerns the gene PDCD1 and colorectal carcinoma.